Ticagrelor NEW

Factory Provide 99% Pure Ticagrelor Powder CAS 274693-27-5 

Introduction

Product Name : Ticagrelor

Other name:1,2-Cyclopentanediol, 3-[7-[[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-, (1S,2S,3R,5S)-

CAS No.: 274693-27-5

MF: C23H28F2N6O4S

MW:522.57

Appearance: White Powder

Melting Point :138-140°C

Melting Point :777.6±70.0 °C(Predicted)

Density :1.67

Storage :Keep in dark place,Sealed in dry,Room Temperature

Ticagrelor, a new platelet aggregation inhibitor successfully developed by AstraZeneca (U.S.), is the world's first reversible combination orally-administered P2Y12 adenosine diphosphate receptor antagonist.

It is used to reduce cardiovascular death and heart attacks in patients with acute coronary syndrome (ACS.) Rapid onset after oral administration, and can effectively improve symptoms of patients with ACS. Thienopyridines is a reversible P2Y12 inhibitor, so it is particularly applicable towards patients who need to undergo anticoagulant therapy before surgery.

Appplication

Ticagrelor is a platelet aggregation inhibitor produced by AstraZeneca. The drug was approved for use in the European Union by the European Commission on December 3, 2010.The drug was approved by the US Food and Drug Administration on July 20, 2011.
Ticagrelor is an antagonist of the P2Y12 receptor.

Ticagrelor is a reversible antagonist of the platelet purinergic P2Y12 receptor, which is the main receptor responsible for ADP-induced platelet aggregation.

Ticagrelor, a new platelet aggregation inhibitor successfully developed by AstraZeneca (U.S.), is the world's first reversible combination orally-administered P2Y12 adenosine diphosphate receptor antagonist.